DEF: Mustang Bio Seeks Shareholder Approval for Equity Plan Boost

Mustang Bio, Inc. is calling its stockholders to a virtual Annual Meeting on December 22, 2025, to vote on director elections, auditor ratification, and significant increases to its employee stock purchase and incentive plans.

Summary

• The Annual Meeting of Stockholders will be held virtually on December 22, 2025, at 9:00 a.m. Eastern Time.
• Stockholders will vote on the election of seven directors, the ratification of KPMG LLP as the independent auditor for 2025, and amendments to two equity compensation plans.
• An amendment to the 2019 Employee Stock Purchase Plan (ESPP) proposes to increase the number of shares issuable by 250,000 shares, raising the total to 259,333, and increase the number of shares subject to a Purchase Right to 10,000.
• An amendment to the 2016 Incentive Plan (EIP) proposes to increase the number of shares issuable by 2,500,000 shares, raising the total to 2,514,666.
• The company effected a 1-for-50 reverse stock split on January 15, 2025, and another on April 3, 2023, with all share and per share information retroactively adjusted.
• As of November 18, 2025, 6,453,701 shares of common stock, 845,385 shares of Class A common stock (convertible to 1,127 common shares), and 250,000 shares of Class A Preferred Stock (convertible to 333 common shares) were outstanding.
• Directors and executive officers as a group beneficially owned less than one percent of outstanding common stock as of November 18, 2025.
• Fortress Biotech, Inc. beneficially owns capital stock representing more than 50% of the voting power, qualifying Mustang Bio as a controlled company under Nasdaq rules.
• No annual cash incentive bonuses were paid to executive officers for 2023 and 2024 to preserve limited cash resources.
• Manuel Litchman, M.D., President, CEO, and Interim CFO, had a salary of $485,500 in 2024 and total compensation of $498,042.
• The company reported a net loss of $15.752 million in 2024, an improvement from a $51.602 million net loss in 2023 and a $77.525 million net loss in 2022.

Sentiment

Score: 3

Explanation: The sentiment is low due to significant proposed dilution, the company's 'controlled company' status with extensive related-party transactions favoring Fortress Biotech, and a history of reverse stock splits. While a decreasing net loss is positive, the overall governance and financial structure present notable concerns for independent shareholders.

Positives

• The proposed amendments to the ESPP and Incentive Plan aim to attract, retain, and motivate valued employees by providing meaningful equity-based incentives.
• Net loss decreased significantly from $77.525 million in 2022 to $15.752 million in 2024, indicating an improving financial trend.
• The company maintains a risk management program overseen by the CEO and regularly reviews credit, liquidity, operations, and compliance risks.
• The Audit Committee consists entirely of independent directors, with an identified financial expert, enhancing financial oversight.

Negatives

• No annual cash incentive bonuses were paid to executive officers for 2023 and 2024, indicating a focus on cash preservation over performance-based cash rewards.
• The company has undergone two reverse stock splits (1-for-50 on January 15, 2025, and another on April 3, 2023), which often signal a need to boost share price to maintain listing requirements or improve market perception.
• Directors and executive officers as a group own less than one percent of the outstanding common stock, potentially indicating limited alignment with broader shareholder interests.
• Significant related-party transactions with Fortress Biotech, Inc., which holds a voting majority and receives substantial fees (2.5% of financing proceeds, 4.5% of annual net sales, and a $0.5M annual consulting fee), raise concerns about potential conflicts of interest and the allocation of company resources.
• The Class A Preferred Stock held by Fortress Biotech, Inc. ensures it will at all times constitute a voting majority, limiting the influence of other stockholders.

Risks

• The company's status as a 'controlled company' due to Fortress Biotech's majority voting power means it is exempt from certain Nasdaq corporate governance rules, such as having a majority of independent directors or fully independent compensation/nominating committees, which could reduce independent oversight.
• The Founders Agreement with Fortress Biotech includes a provision that Fortress and its affiliates have no fiduciary duty to communicate corporate opportunities to Mustang Bio, potentially diverting valuable opportunities.
• The proposed increase in shares available under the ESPP (250,000 shares) and the 2016 Incentive Plan (2,500,000 shares) could lead to significant dilution for existing stockholders.
• Executive severance benefits are subject to reduction to avoid excise taxes under Sections 280G and 4999 of the IRC, indicating potential exposure to these tax implications.
• A delinquent Section 16(a) report for Dr. Litchman (covering two transactions) due to administrative error highlights a risk in compliance and reporting accuracy.

Future Outlook

The company anticipates needing the additional 2,500,000 shares requested under the 2016 Incentive Plan for the next year under normal circumstances to continue offering meaningful equity-based incentives. The Board expects a representative of KPMG LLP to be present at the Annual Meeting to make a statement and answer questions.

Management Comments

• Manuel Litchman, M.D., President, CEO, and Interim CFO, stated: "Your vote is important. It is important that your stock be represented at the meeting regardless of the number of shares you hold."
• The Board believes it is in the best interests of the Company to determine the separation of CEO and Chairman roles based on the Company's direction and current Board membership, and currently, having a director who is also the CEO serve as Chairman is not in the best interest of stockholders.
• The Board believes that the current process in place functions effectively to select director nominees who will be valuable members of the Board, despite not having a written charter for a nominating committee.
• The Compensation Committee decided not to pay 2023 and 2024 annual cash incentive bonuses to preserve the company's limited cash resources.

Industry Context

As a biotechnology company focused on research and development of novel therapies, Mustang Bio's reliance on equity-based compensation plans is typical for attracting and retaining talent in a competitive labor market. The significant net losses are also common for early-stage biotech firms heavily investing in R&D. The 'controlled company' status, however, is a specific governance structure that deviates from broader industry trends towards greater independent board oversight, particularly for publicly traded companies.

Comparison to Industry Standards

• The company's 'controlled company' status, stemming from Fortress Biotech's majority voting power, deviates from the standard corporate governance practice for most publicly traded companies, which typically require a majority of independent directors and fully independent key committees (compensation, nominating).
• The proposed increases in shares for the Employee Stock Purchase Plan (ESPP) and the 2016 Incentive Plan are common mechanisms in the biotechnology industry to incentivize and retain employees, aligning with practices seen in comparable R&D-intensive firms.
• The occurrence of two reverse stock splits (April 2023 and January 2025) suggests the company has faced challenges in maintaining its stock price, a situation often seen in smaller, development-stage biotech companies, but it is generally viewed negatively compared to industry peers with stable or appreciating stock values.
• The substantial related-party transactions with Fortress Biotech, including significant fees and a lack of fiduciary duty for corporate opportunities, are not standard for independent public companies and could be viewed unfavorably compared to best-in-class governance benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• One Form 4 for Dr. Litchman (covering two transactions) was filed untimely on June 4, 2024, due to administrative error, indicating a past compliance issue with Section 16(a) reporting requirements.

Related Party Transactions

• Founders Agreement with Fortress Biotech, Inc. (amended and restated July 26, 2016) has a 15-year term, automatically renewing, and includes various fees and equity provisions.
• Fortress Biotech holds 250,000 shares of Class A Preferred Stock, which at all times constitutes a voting majority and is convertible into common stock.
• Fortress Biotech receives annual stock dividends equal to 2.5% of the company's fully-diluted outstanding capitalization on each January 1.
• The company pays an equity fee to Fortress Biotech equal to 2.5% of the gross amount of any equity or debt financing, which amounted to 23,450 shares in 2024 and 1,319 shares issuable in 2023.
• The company pays a cash fee to Fortress Biotech equal to 4.5% of its annual net sales.
• In the event of a Change in Control, the company will pay Fortress Biotech a one-time fee equal to five times the product of (A) net sales for the preceding 12 months and (B) 4.5%.
• A Management Services Agreement with Fortress Biotech requires an annual consulting fee of $0.5 million (increasing to $1.0 million if net assets exceed $100 million), with $0.5 million expensed in both 2024 and 2023.
• Fortress Biotech and its affiliates, including all Board members, have no fiduciary or other duty to communicate or present corporate opportunities to Mustang Bio.
• Fortress Biotech pays for certain expenses on Mustang Bio's behalf, recorded as 'Payables and accrued expenses related party'.
• Dr. Lindsay A. Rosenwald (Director, Chairman/President/CEO of Fortress) and Mr. David Jin (Director, CFO/Head of Corporate Development of Fortress) receive director compensation, including cash fees and annual stock awards.
• An Advisory Agreement with Caribe BioAdvisors, LLC (owned by Michael S. Weiss, Chairman of the Board) provides for an annual cash fee of $60,000 for Mr. Weiss's advisory services.

Stakeholder Impact

• Shareholders face potential significant dilution from the proposed increases in shares for the ESPP and Incentive Plan.
• Shareholders' voting power is significantly constrained by Fortress Biotech's Class A Preferred Stock, which ensures a voting majority.
• Employees benefit from enhanced opportunities to purchase company stock through the ESPP and receive equity incentives under the EIP, potentially improving retention and motivation.
• Management (executive officers) did not receive cash incentive bonuses for 2023 and 2024, impacting their short-term cash compensation, but their equity incentives are being expanded.
• Fortress Biotech, as a controlling shareholder and related party, benefits substantially from various fees, equity grants, and consulting services, potentially at the expense of other stakeholders.
• Creditors and suppliers may be indirectly impacted by the company's financial health and cash preservation strategies, including the decision to forgo executive cash bonuses.

Next Steps

• Stockholders will vote on the proposed matters at the virtual Annual Meeting on December 22, 2025.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results in a Current Report on Form 8-K within four business days after the meeting.
• The Board intends to grant Mr. Jin his Initial Equity Grant and subsequent Re-Election Equity Grants following the 2025 Annual Meeting.

Key Dates

Recommendation

While the company shows an improving trend in reducing its net loss, the significant proposed dilution from expanding equity compensation plans, coupled with the company's 'controlled company' status and extensive related-party transactions with Fortress Biotech, presents considerable risks and potential conflicts of interest. The historical reverse stock splits also indicate past challenges. For existing investors, a 'hold' recommendation is appropriate to monitor the impact of these governance and dilution factors, as well as the company's progress in its R&D pipeline. New investors should approach with caution due to the complex governance structure and potential for further dilution.

Keywords

Proxy Statement, Annual Meeting, Stockholder Vote, Employee Stock Purchase Plan, Incentive Plan, Equity Compensation, Reverse Stock Split, Corporate Governance, Related Party Transactions, Fortress Biotech, Dilution, Biotechnology, SEC Filing